A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer - Pilot immunotherapy study with GSK3377794 (NY-ESO T-cells) in NSCLC patients.

Start Date28 Feb 2020

Sponsor / Collaborator

GSK Plc

NCT06703346

/ Active, not recruitingPhase 2

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants with NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Start Date31 Dec 2019

Sponsor / Collaborator

Adaptimmune Ltd.

NCT05993299

/ Active, not recruitingPhase 2

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Start Date31 Dec 2019

Sponsor / Collaborator

Adaptimmune Ltd.

100 Clinical Results associated with Letetresgene autoleucel

100 Translational Medicine associated with Letetresgene autoleucel

100 Patents (Medical) associated with Letetresgene autoleucel

Literatures (Medical) associated with Letetresgene autoleucel

03 Feb 2025·CLINICAL CANCER RESEARCH

Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Article

Author: Altan, Mehmet ; Ramos-Hernandez, Natalia ; Tarek, Nidale ; Felip, Enriqueta ; Zauderer, Marjorie ; O’Cearbhaill, Róisín Eilish ; Zajic, Stefan ; Chisamore, Michael ; Schoenfeld, Adam J. ; Corigliano, Ellie ; Lopes, Gilberto ; Villaruz, Liza C. ; Furqan, Muhammad ; Govindan, Ramaswamy ; Suchindran, Sunil ; Jenkins, Ben ; Carlisle, Jennifer W. ; Edelman, Martin J. ; Goodison, Sophia ; Eleftheriadou, Ioanna ; Calvo, Emiliano ; Heymach, John V. ; Hiltermann, T. Jeroen N. ; Neal, Joel

Abstract:

Purpose::

The study aims to evaluate the safety, tolerability, and antitumor response of letetresgene autoleucel (lete-cel), genetically modified autologous T cells expressing a T-cell receptor specific for New York esophageal squamous cell carcinoma 1 (NY-ESO-1)/LAGE-1a shared epitope, alone or in combination with pembrolizumab, in HLA-A*02–positive (HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06) patients with NY-ESO-1– and/or LAGE-1a–positive non–small cell lung cancer.

Patients and Methods::

Study 208749 was a single-arm study of lete-cel alone. Study 208471 was a multiarm study of lete-cel alone or in combination with pembrolizumab in patients with advanced or recurrent non–small cell lung cancer.

Results::

More than 2,500 patients were screened for target expression. In the multiarm study, 738 (45%) of 1,638 tested patients were HLA-A*02–positive. NY-ESO-1 and LAGE-1a testing was positive in 12% (62/525) and 4% (15/348) of tested patients, respectively. Forty-one patients positive for HLA-A*02 and antigen expression were screened in the single-arm study. Overall, 43 patients underwent leukapheresis and 18 received lete-cel across studies. Lete-cel demonstrated a manageable safety profile. No fatal treatment-related serious adverse events (AE) were reported in either study. Cytopenias and cytokine release syndrome were the most common treatment-emergent AEs. Combining pembrolizumab with lete-cel did not seem to increase toxicity over lete-cel alone. Limited antitumor activity was observed; one of 18 patients had a durable response persisting for 18 months. Pharmacokinetic data showed similar T-cell expansion in all patients.

Conclusions::

Extensive HLA-A*02 and antigen expression testing was performed to identify potential participants. Lete-cel was generally well tolerated and had no unexpected AEs. Antitumor activity was observed in a limited number of patients.

11 Apr 2023·Blood advances

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma

Article

Author: D’Souza, Jimson W. ; Rapoport, Aaron P. ; Faitg, Thomas ; Nishihori, Taiga ; Urbano, Alisa ; Zajic, Stefan ; Hoffman, James E. ; Suchindran, Sunil ; Huff, Anne ; Chisamore, Michael ; Kapoor, Gurpreet S. ; Eleftheriadou, Ioanna

Abstract:

This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794), a genetically modified autologous T-cell therapy targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L antigen family member 1 isoform A (LAGE-1a)–positive myeloma cells, alone or in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. Eligible patients expressed NY-ESO-1 and/or LAGE-1a and either HLA-A∗02:01, ∗02:05, or ∗02:06. Patients received lete-cel single infusion alone (arm 1) or with pembrolizumab (arm 2). 127 patients were screened, and 6 patients (3 per arm) were enrolled; patients in arm 1 and 2 received lete-cel alone, or with pembrolizumab, respectively. All patients exhibited grade 3/4 cytopenias, which resolved or improved to grade 1. One patient (arm 1) had grade 3/4 lete-cel–related adverse events (AEs); 2 patients (arm 2) had grade 3/4 AEs related to lete-cel and lymphodepletion. Three patients with grade 1/2 cytokine release syndrome (CRS) exhibited elevated post–lete-cel interleukin-6 levels versus those without CRS. Pooled overall response rate was 50% including 1 patient each with confirmed clinical response, very good clinical response, and partial response, and progression-free survival ranged from 1.3 to 5.2 months. Responders (arm 1: n = 1; arm 2: n = 2) had a time-to-response of 3 weeks, duration of response of 2.1 months. Two responders, but no nonresponders, exhibited elevated cytokine levels after lete-cel infusion. Lete-cel had a manageable safety profile and demonstrated clear but transient antitumor activity in patients with relapsed/refractory multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT03168438.

01 Dec 2019·Journal for immunotherapy of cancerQ2 · MEDICINE

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Q2 · MEDICINE

ArticleOA

Author: Tipping, Alex J ; Binder, Gwendolyn K ; Wilky, Breelyn ; Lowther, Daniel E ; Bath, Natalie ; Trivedi, Trupti ; Abdul Razak, Albiruni R ; Chow, Warren A ; Dryer-Minnerly, Rebecca ; Melchiori, Luca ; Navenot, Jean-Marc ; Nunez, Daniel ; Van Tine, Brian A ; Araujo, Dejka M ; Winkle, Erin Van ; Wang, Ruoxi ; Iyengar, Malini ; Demetri, George D ; Grupp, Stephan A ; Betts, Gareth ; Fayngerts, Svetlana ; Ramachandran, Indu ; Glod, John ; Druta, Mihaela ; Basu, Samik ; Mackall, Crystal L ; Chagin, Karen ; D'Angelo, Sandra P ; Amado, Rafael

BACKGROUND:

Gene-modified autologous T cells expressing NY-ESO-1^c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma (SS). The factors contributing to gene-modified T-cell expansion and the changes within the tumor microenvironment (TME) following T-cell infusion remain unclear. These studies address the immunological mechanisms of response and resistance in patients with SS treated with NY-ESO-1 SPEAR T-cells.

METHODS:

Four cohorts were included to evaluate antigen expression and preconditioning on efficacy. Clinical responses were assessed by RECIST v1.1. Engineered T-cell persistence was determined by qPCR. Serum cytokines were evaluated by immunoassay. Transcriptomic analyses and immunohistochemistry were performed on tumor biopsies from patients before and after T-cell infusion. Gene-modified T-cells were detected within the TME via an RNAish assay.

RESULTS:

Responses across cohorts were affected by preconditioning and intra-tumoral NY-ESO-1 expression. Of the 42 patients reported (data cut-off 4June2018), 1 patient had a complete response, 14 patients had partial responses, 24 patients had stable disease, and 3 patients had progressive disease. The magnitude of gene-modified T-cell expansion shortly after infusion was associated with response in patients with high intra-tumoral NY-ESO-1 expression. Patients receiving a fludarabine-containing conditioning regimen experienced increases in serum IL-7 and IL-15. Prior to infusion, the TME exhibited minimal leukocyte infiltration; CD163⁺ tumor-associated macrophages (TAMs) were the dominant population. Modest increases in intra-tumoral leukocytes (≤5%) were observed in a subset of subjects at approximately 8 weeks. Beyond 8 weeks post infusion, the TME was minimally infiltrated with a TAM-dominant leukocyte infiltrate. Tumor-associated antigens and antigen presentation did not significantly change within the tumor post-T-cell infusion. Finally, NY-ESO-1 SPEAR T cells trafficked to the TME and maintained cytotoxicity in a subset of patients.

CONCLUSIONS:

Our studies elucidate some factors that underpin response and resistance to NY-ESO-1 SPEAR T-cell therapy. From these data, we conclude that a lymphodepletion regimen containing high doses of fludarabine and cyclophosphamide is necessary for SPEAR T-cell persistence and efficacy. Furthermore, these data demonstrate that non-T-cell inflamed tumors, which are resistant to PD-1/PD-L1 inhibitors, can be treated with adoptive T-cell based immunotherapy.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT01343043 , Registered 27 April 2011.

News (Medical) associated with Letetresgene autoleucel

21 Mar 2025

·www.biospace.com

Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy

iStock, hurca Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money. Despite the “increasing” momentum of its engineered T cell therapy Tecelra, Adaptimmune on Thursday expressed concern about its ability to continue as a business. “There is substantial doubt about our ability to continue,” the biotech wrote in a news release, adding that it will continue to “implement cost reduction measures.” In particular, Adaptimmune revealed on a Thursday investor call that it would pause work on two early-stage assets : the PRAME-targeting ADP-600 being developed for solid tumors and the anti-CD70 molecule ADP-520 for hematological malignancies. Both programs were undergoing IND-enabling studies. The company’s cash crunch comes as it works on launching Tecelra, the first FDA-approved engineered T cell therapy for solid tumors. The therapy won the FDA’s blessing in August 2024, allowing its use in patients with unresectable or metastatic synovial sarcoma. Adaptimmune has so far prepared 10 patients for treatment across 20 activated authorized treatment centers, according to its Thursday release. Adaptimmune is also currently exploring “all strategic options” for its business and all of its programs, for which it has enlisted TD Cowen’s help, CEO Adrian Rawcliffe said on the investor call. “This includes potential partnerships or collaborations, strategic combinations, various financial transactions and multiple pipeline monetization opportunities,” he added. Adaptimmune had just under $147 million in cash, cash equivalents and marketable securities at the end of 2024, according to its Q4 and full-year business update . The biotech expects to hit profitability in 2027, Rawcliffe said on the call. With two patients invoiced and no reimbursement denials to date, Tecelra has so far made $1.2 million for Adaptimmune. The company expects to have its full network of 30 treatment centers online by the end of 2025. “We feel very confident that the consensus analyst forecast of approximately $25 million of sales in 2025 is very achievable,” Rawcliffe said on the call. Meanwhile, Adaptimmune is also building toward its next potential launch, the TCR T cell therapy lete-cel, which in November 2024 cleared the mid-stage IGNYTE-ESO trial. In patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma, lete-cel elicited a 42% response rate that lasted for a median of 12.2 months in the overall study population. Adaptimmune is working on filing a Biologics License Application for lete-cel later this year and expects the therapy to hit the market in 2027, Rawcliffe said on Thursday, forecasting peak sales of around $400 million. “We estimate that lete-cel will eventually make up over 60% of our combined sarcoma franchise revenue,” he added.

Cell TherapyImmunotherapyClinical ResultDrug ApprovalClinical Study

20 Mar 2025

·www.prnewswire.com

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive Directors Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up To support the acceleration of proof-of-concept cancer vaccine, ITOP1, into Phase I/IIa clinical development, to prevent the recurrence of oesophageal cancers OXFORD, England, March 20, 2025 /PRNewswire/ -- Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to transition into a clinical stage company with lead vaccine candidate, ITOP1, to treat patients with oesophageal cancer. Dan Menichella is a seasoned biotech executive, who brings extensive experience in vaccine development, strategic partnerships, and rapid corporate growth. As CEO and CBO of CureVac's U.S. subsidiary, he built out the Boston operation, delivered four deals in his first year – including a multi-product cancer vaccine collaboration with Eli Lilly worth up to $1.7 billion. He became CEO of CureVac AG in 2018. Before CureVac, Dan served as CBO at Bamboo Therapeutics, where he spearheaded the in-licensing of a Duchenne muscular dystrophy programme, unlocking the company's $43 million series A and subsequent $645 million buyout by Pfizer. He has significant fundraising experience and led many large transactions, including partnerships with Lilly, Biogen, and Takeda, and supported IPO's and successful exits. Dan's proven ability to forge high-value alliances and advance breakthrough therapeutics underscores his expertise in guiding life science ventures to success. Dan Menichella, incoming Non-Executive Director at Infinitopes, added: "I am honoured to join Infinitopes' Board of Directors at this exciting time for the company, as we begin the Phase I/IIa clinical trial in oesophageal cancer. Infinitopes is a highly innovative company with a strong commitment to cancer research. Its approach holds the promise to revolutionise cancer treatments for patients, and I am excited and committed to support Jonathan and the team as they embark on this groundbreaking path." Jo Brewer, PhD, is a recognised industry leader in cancer immunotherapy and cell therapies, with over 20 years of experience bringing cutting-edge treatments from discovery to the clinic. Currently serving as CSO at Adaptimmune, she has been instrumental in developing autologous and allogeneic T-cell therapies, leading to Tecelra®, the first engineered TCR-T cell therapy for solid tumours to reach the market. As a founding scientist at Adaptimmune, Jo played a critical role in the development of multiple immunotherapies, including lete-cel for sarcoma and uza-cel, now partnered with Galapagos. She has built and led multiple research teams at Adaptimmune and played a significant role in the upscaling from a small biotech to 500+ employees, driving innovation across discovery and translational science. Jo Brewer, PhD, incoming Non-Executive Director at Infinitopes, remarked: "Infinitopes, with its pioneering approach to precision cancer vaccines, driven by its innovative AI/ML-powered Immunomics™ platform, has the potential to revolutionise how we target and treat cancers. The precision and speed that its world-leading clinicians and scientists are advancing its novel immunotherapies is truly impressive, and I look forward to joining the Board at such a critical time of clinical development, to contribute my expertise to bringing these transformative treatments to patients." Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said : "I'm delighted to welcome Dan and Jo to our Board at a pivotal time, as we prepare to begin our first clinical trial for ITOP1, our proof-of-concept cancer vaccine candidate, initially targeting oesophageal cancers. Their leadership and deep expertise in immuno-oncology and biotech growth is invaluable as we advance our AI/ML-driven antigen discovery platform and push the boundaries of what is possible in cancer vaccine development. Their decision to join Infinitopes reflects the strength of our technologies, our ambitious mission, and the future potential impact for patients worldwide." In April 2024 Infinitopes announced its oversubscribed £12.8 million seed financing to advance its AI/ML Precision Immunomics™ bespoke antigen discovery platform. This proprietary technology enables the safe and highly accurate design of 'best-in-class' therapeutics for multiple cancer indications. Guided by an exceptional leadership team and distinguished Scientific Advisory Board (SAB) of world-class clinicians, scientists, and regulatory experts, Infinitopes is poised to initiate its vaccine candidate, ITOP1, in a highly anticipated double-blind, randomised, placebo-controlled Phase I/IIa clinical trial. This trial is aimed at treating patients with oesophageal cancer and is expected to begin at four UK NHS university cancer centres in the first half of 2025. About Infinitopes Infinitopes Ltd is a soon to be clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world leading platforms, in precision target discovery and in high efficiency, vector delivery systems, to develop immunologically durable vaccines against multiple solid tumour indications. The lead vaccine candidate is expected to begin Phase I/IIa trials in H1' 25. Infinitopes has gathered together in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, clinical trials and regulation, winning an 'Innovative Licensing and Access Pathway' (ILAP) innovation passport from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. Infinitopes has also won two prestigious, maximum size, nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022) and a Future Economy Investor Partnership (in 2023). Since incorporation, the Infinitopes team has raised nearly $20m from sector expert investors including Cancer Research Horizons, Cancer Research Institute, Kindred Capital, Manta Ray Ventures, Martlet, Meltwind, Octopus Ventures, Saras Capital, Wilbe and the Fundación CRIS Contra el Cáncer, funding its rapid growth from three academic co-founders to 28 full time equivalents. It is now the largest tenant of Oxford University's BioEscalator innovation accelerator. For more information, visit SOURCE Infinitopes WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineIPOExecutive ChangeImmunotherapy

15 Nov 2024

·endpts.com

Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers

Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million over the next few years through 2028. The company said it will axe 33% of its employees in the first quarter of next year, according to its third-quarter earnings release Wednesday. Adaptimmune had 449 employees at the end of 2023. It also said it will stop enrollment in a Phase 2 trial of its T cell therapy, uza-cel, in platinum-resistant ovarian cancer. “We will reduce our UK footprint and research functions and suspend clinical trial activities with uza-cel for ovarian cancer, which will remove the associated CMC and development costs in the coming years,” CEO Adrian Rawcliffe said on an earnings call. But Rawcliffe added that its work with uza-cel is not yet done as its collaboration with Galapagos in head and neck cancer will not be affected, with plans for a clinical proof-of-concept trial still in place. Nonetheless, these moves reflect Adaptimmune’s mission to “redefine itself as a sarcoma-focused business,” by shifting its resources towards its T cell immunotherapy Teclera and another late-stage sarcoma candidate, lete-cel, the company said. Teclera won an FDA accelerated approval in August for synovial sarcoma. The company plans to start a rolling BLA for lete-cel in advanced or metastatic myxoid/round cell liposarcoma and synovial sarcoma by the end of 2025. The biotech, which has headquarters in Philadelphia and Oxford, UK, believes Teclera and lete-cell could together hit $400 million in peak US sales. As for the rollout of Teclera, the drugmaker is working with so-called “sarcoma centres of excellence” to establish them as authorized treatment centers (ACTs), a process that can take “several months to complete,” according to TD Cowen analysts. So far, nine ACTs have been established, which is at the upper end of Adaptimmune’s guidance of six to ten centers in the first 90 days of launch, Rawcliffe said during the earnings call. “We have an additional four sites that have signed contracts and a further 15 sites that are in active contract negotiations,” he added. Earlier in its pipeline, Adaptimmune is advancing two preclinical candidates: ADP-600 for solid tumors and ADP-520 for hematological malignancies, among other indications. The company said it is currently in “active discussions” with an eye to partnering with these programs.

ImmunotherapyCell TherapyAccelerated ApprovalPhase 2

100 Deals associated with Letetresgene autoleucel

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
LAGE-1a Positive Solid Tumors	Phase 2	United States	Adaptimmune Ltd.	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Canada	Adaptimmune Ltd.	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	France	Adaptimmune Ltd.	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Italy	Adaptimmune Ltd.	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Netherlands	Adaptimmune Ltd.	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Spain	Adaptimmune Ltd.	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	United Kingdom	Adaptimmune Ltd.	31 Dec 2019
NY-ESO-1 Positive Solid Tumors	Phase 2	United States	Adaptimmune Ltd.	31 Dec 2019
NY-ESO-1 Positive Solid Tumors	Phase 2	Canada	Adaptimmune Ltd.	31 Dec 2019
NY-ESO-1 Positive Solid Tumors	Phase 2	France	Adaptimmune Ltd.	31 Dec 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02992743 (NCT02992743, Pubmed \| J Clin Oncol)	Phase 2	Myxoid Liposarcoma NY-ESO-1-positive \| HLA-A02:05 \| HLA-A02:06-positive	23	Letetresgene Autoleucel (Cohort 1 (Reduced-dose lymphodepletion regimen))	rtxxejuyhg(adiiiiyege) = candgwkgpa bzmrawfmld (hjiuaauudg, 2.5 - 55.6) View more	Positive	21 Jan 2025
				Letetresgene Autoleucel (Cohort 2 (Standard-dose lymphodepletion regimen))	rtxxejuyhg(adiiiiyege) = vwlaasevoj bzmrawfmld (hjiuaauudg, 12.2 - 73.8) View more
NCT03967223 (IGNYTE-ESO, Company_Website) Manual	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	64	lete-cel	aarhkspeql(lgnqdwzsuj) = ebfssovlsy csnnxwuokz (ikljqovnoc ) View more	Positive	13 Nov 2024
				lete-cel (synovial sarcoma)	aarhkspeql(lgnqdwzsuj) = whiqksgopp csnnxwuokz (ikljqovnoc ) View more
NCT03967223 (IGNYTE-ESO, ASCO2024)	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma NY-ESO-1	98	Lete-cel	vgyxcopgrv(rznexpdvte) = xujygfkdbc zzlzizbkdp (tczmvgjfyh, 20.3% - 62.3%) View more	Positive	24 May 2024
SITC2023	Not Applicable	Synovial Sarcoma NY-ESO-1 positive	-	lete-cel 10% dose on day 1, 30% on day 2, 60% on day 3	unsvneomea(ffeddezawg) = eastchztpi apcnfeyzzc (dlsdkixlbz, 33% - 57%)	-	02 Nov 2023
				lete-cel single dose	unsvneomea(ffeddezawg) = rsvokrhbca apcnfeyzzc (dlsdkixlbz, 33% - 57%)
NCT03967223 (IGNYTE-ESO , Corporate Publications) Manual	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma Third line	45	lete-cel	glcblohune(dbgipxanme) = eetasrvqjs uyldxspnio (ppcwszhycb ) View more	Positive	31 Oct 2023
NCT05993299 (CTgov)	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	7	fludarabine+cyclophosphamide+lete-cel	vbcuwvtnwk = dzqglyuhpi aasdbjdzxj (dbezgvjjqe, movcfxzphy - rypfileooa) View more	-	16 Oct 2023
NCT02992743 (MRCLS \| NCT02992743, CTgov)	Phase 2	Myxoid Liposarcoma	23	GSK3377794 (Reduced Lymphodepletion Dose Plus GSK3377794)	hfamjgviob = eryhcsqvyt ybuakpnxqv (tlrdnvzhnx, zediejftqq - dyzxuwzuco) View more	-	28 Nov 2022
				GSK3377794 (Standard Lymphodepletion Dose Plus GSK3377794)	hfamjgviob = pfqqxatlpp ybuakpnxqv (tlrdnvzhnx, bebtmwfeyq - reumaqkgmw) View more
NCT02992743 (MRCLS, ASCO2022) Manual	Phase 2	Myxoid Liposarcoma	20	fludarabine+cyclophosphamide+GSK3377794 (Cohort 1 [C1])	qbrgdnqsql(ygispvvqpl) = uvangjuumj rdrtmdxway (legxejangf ) View more	Positive	02 Jun 2022
				fludarabine+cyclophosphamide+GSK3377794 (Cohort 2 [C2])	qbrgdnqsql(ygispvvqpl) = quxzbgvjve rdrtmdxway (legxejangf ) View more
NCT03168438 (CTgov)	Phase 1	Relapse multiple myeloma \| Multiple Myeloma	6	fludarabine+cyclophosphamide+GSK3377794 (GSK3377794)	nlpleumvrr = nllifjhawz vyopocxtbh (kkcyaapiqd, qmubmvhfqf - jeynecuvoe) View more	-	11 Jan 2022
				Pembrolizumab+GSK3377794 (GSK3377794+Pembrolizumab)	nlpleumvrr = njfzfpwuec vyopocxtbh (kkcyaapiqd, xxcnfobgtv - hrqyqgline) View more
ESMO2021	Not Applicable	Ovarian Cancer \| Squamous Cell Carcinoma of Head and Neck \| Bladder Cancer ... View more	-	Letetresgene autoleucel (lete-cel; GSK3377794)	xrgothmyyf(ussoqufwkf) = dcldlzymaz wzlohdrowj (meaewmjxix ) View more	-	16 Sep 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Letetresgene autoleucel

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation